Century Therapeutics and Bristol-Myers Squibb Form Strategic Partnership to Develop Allogeneic Cell Therapies Derived from iPSCs

Excerpt Century Therapeutics and Bristol Myers Squibb have formed a strategic partnership and license agreement to develop and commercialize four iPSC-derived, engineered natural killer cell projects for hematologic and solid cancers. Article Summary Through this collaboration, Century Therapeutics will expand its pipeline of iPSC-derived cell therapy for haematological and solid tumours. As part of the agreement, the […]

GHO Capital Invests in UK based Cell Therapies Focused CDMO – RoslinCT


Excerpt RoslinCT, advanced cell therapy-focused CDMO has announced the investment from Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare to support its development and manufacturing capacity. Article Summary RoslinCT will greatly boost its development and manufacturing capacity with GHO’s funding, allowing it to support client acquisition and product […]

Quell Therapeutics Has Raise $156 million in Series B Funding to Accelerate its T Regulatory (Treg) Cell Therapy

Excerpt Quell Therapeutics Ltd., the developer of modified T-regulatory (Treg) cell therapies for immune diseases, has secured $156 million in an anticipated Series B fundraising round. The funding will be used to support the development of Quell Therapeutics products “QEL-001” for liver transplantation in addition to company’s product pipeline across several immune related diseases as well […]

Cellevolve Partners with QIMR Berghofer Medical Research Institute to Push Novel Off-the-Shelf T-Cell Therapy, Trial for Progressive Multifocal Leukoencephalopathy

Excerpt Cellevolve Bio, cell therapy focused company, reported collaboration with QIMR Berghofer Medical Research Institute and its cell therapy production facility Q-Gen Cell Therapeutics. Allogeneic cell therapies that are available off-the-shelf may have a number of advantages, notably expedited delivery to patients with fast changing diseases like PML. Further, Cellevolve plans to team up with BeTheMatch […]

cell therapy blog image

TScan Therapeutics Completes the Construction of its T-Cell Therapies Focused Manufacturing Facility

Excerpt TScan Therapeutics, Inc., focused on the development of engineered T cell therapies (TCR-T) for the cancer treatment has announced that the establishment of its state-of-the-art GMP manufacturing facility to manufacture Phase I/II TCR-T therapies. Article Summary This new facility is built to support the manufacturing of company’s top lead liquid tumor candidates, TSC-100 and […]

stem cell image

Gene Therapy Focused US Biotech, Passage Bio Announces Pipeline Expansion and Clinical Program Update

Excerpt Passage Bio, a clinical-stage genetic medicines company focused on creating breakthrough medicines for central nervous system disorders has announced the growth of its pipeline and presented an update on its three clinical projects. Article Summary The company has announced that exercise of two additional options with University of Pennsylvania’s Gene Therapy Program aligned with their […]

stem cell image

An innovative, Cell Therapy based CDMO Announces the Expansion of its Facility

Lykan Bioscience, a contract development and manufacturing organisation specialising in cell-based therapeutics, announced the expansion of its facility in Hopkinton, Massachusetts. The increasing need for cell therapy process research and production is driving the expansion and establishment of new innovation lab. As part of the facility expansion plan, seven ISO 7 cGMP suites with autologous […]

WuXi ATU Opens New Facility in Philadelphia for Advanced Therapies Testing


Excerpt WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, has announced the official launch of its testing facility located in Philadelphia’s Navy Yard. Article Summary The new facility with 140,000 square feet of labs, will improve the firm’s Contract Testing, Development, and Manufacturing Organization business model by expanding the previous testing capacity. This will allow the company to meet […]

Lykan Bioscience to Increase Its Cell Therapy Process Development and Manufacturing Capacity by 90%


Excerpt Lykan Bioscience, a contract development and manufacturing organisation specialising in cell-based therapeutics, announced the expansion of its facility in Hopkinton, Massachusetts. The increasing need for cell therapy process research and production is driving the expansion and establishment of new innovation lab. Article Summary As part of the facility expansion plan, seven ISO 7 cGMP suites with autologous and allogeneic […]

Sanofi Invests $60 Million in an Eye-Focused Gene Therapy Biotech Company


Excerpt Sanofi is investing up to $60 million in a UK based gene therapy start up, Gyroscope Therapeutics. The company is developing therapies for a prevalent form of blindness. The funds are raised after the firm announced positive safety data from their gene – therapy (GT005). Article Summary Gyroscope was founded by U.K. based healthcare investment business – Syncona Ltd. Syncona […]

Blackstone Life Sciences Supports Autolus Therapeutics with $250 Million Investment


Excerpt Autolus Therapeutics plc, a clinical-stage biopharmaceutical company that develops cell therapies for cancer treatment has announced a financial agreement with Blackstone Life Sciences for $250 million. Article Summary Autolus will receive up to $250 million in equity and product financing from Blackstone which will enable the development of CART cell therapy product – obecabtagene autoleucel (obe-cel), […]

Adaptimmune Enters into a Strategic Collaboration with Genentech

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies

Excerpt An agreement between Adaptimmune and Genentech is set to drive “off-the-shelf” cancer-targeted cell therapy advancements and commercialization with an initial payment of $150 million to Adaptimmune. The partnership also aims to develop a first-of-its-kind personalized cell therapy platform to enable patients to receive curated T-cell products for their individual cancer treatment needs. Adaptimmune may […]